<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nogr</journal-id><journal-title-group><journal-title xml:lang="ru">Экспериментальная и клиническая гастроэнтерология</journal-title><trans-title-group xml:lang="en"><trans-title>Experimental and Clinical Gastroenterology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-8658</issn><publisher><publisher-name>«Global Media Technologies»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31146/1682-8658-ecg-222-2-44-49</article-id><article-id custom-type="elpub" pub-id-type="custom">nogr-2580</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ ГАСТРОЭНТЕРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL GASTROENTEROLOGY</subject></subj-group></article-categories><title-group><article-title>Клиническое улучшение некоторых показателей активности неалкогольной жировой болезни печени после коррекции дисбиоза кишечника с помощью пищевых волокон</article-title><trans-title-group xml:lang="en"><trans-title>Clinical improvement of some indicators of the activity of non-alcoholic fatty liver disease after correction of intestinal dysbiosis with dietary fiber</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1757-0774</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крылова</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Krylova</surname><given-names>I. A.</given-names></name></name-alternatives><email xlink:type="simple">raznoe.2009@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5905-1895</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лямин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lyamin</surname><given-names>A. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2639-0003</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Купаев</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kupaev</surname><given-names>V. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Самарский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Samara State Medical University of the Ministry of Healthcare of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>26</day><month>03</month><year>2024</year></pub-date><volume>0</volume><issue>2</issue><fpage>44</fpage><lpage>49</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Крылова И.А., Лямин А.В., Купаев В.И., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Крылова И.А., Лямин А.В., Купаев В.И.</copyright-holder><copyright-holder xml:lang="en">Krylova I.A., Lyamin A.V., Kupaev V.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nogr.org/jour/article/view/2580">https://www.nogr.org/jour/article/view/2580</self-uri><abstract><p>Актуальность. Метаболические нарушения при неалкогольной жировой болезни печени играют значительную роль в развитии и прогрессировании сердечно-сосудистых заболеваний, ускоряя их возникновение, утяжеляя их течение и исходы. Возникновение и поддержание хронического стадийного течения (от жирового гепатоза и неалкогольного стеатогепатита до прогрессирующего фиброза печени) заболевания связано с количественным и качественным изменением состава кишечной микрофлоры. При этом амбулаторные пациенты могут считать себя здоровыми, что затрудняет реализацию комплексной программы лечения. Особенности сочетания клинических, лабораторных и микробиологических характеристик пациентов, имеющих стеатоз печени, требуют детального изучения для наиболее раннего выявления терапевтических мишеней, диагностических и прогностических средств и эффективной их коррекции. Цель исследования: определить клинические, лабораторные и микробиологические особенности пациентов с неалкогольной жировой болезнью печени. Материал и методы: собраны клинические, лабораторные и микробиологические данные амбулаторных пациентов, рассчитаны антропометрические показатели. Статистический анализ: Microsoft Excel 2010 и StatTech v.3.1.8 (ООО «Статтех», Россия) с оценкой на нормальность распределения и критерия хи-квадрат, точного критерия Фишера. Различия оценивали непараметрическим анализом при уровне значимости p&lt;0,05. Результаты. Пациенты отнесены к группе наблюдения при наличии НАЖБП или к группе сравнения при ее отсутствии. У многих пациентов группы наблюдения выявлено наличие метаболического синдрома и/или абдоминальный тип ожирения, сопровождающиеся астеническим синдромом, функциональными нарушениями билиарного тракта, нарушениями липидного и углеводного обменов. В просветной микрофлоре кишечника пациентов группы наблюдения достоверно чаще обнаружено наличие представителей Pseudomonas spp. Коррекция микробиологических нарушений путем добавления пищевых волокон в рацион питания обеспечила клиническое улучшение. Заключение. Для наиболее ранней диагностики и эффективной коррекции нарушений, возникающих в ходе развития НАЖБП, кроме клинических и лабораторных данных можно использовать микробиологические характеристики пациентов.</p></abstract><trans-abstract xml:lang="en"><p>Relevance. Metabolic disorders in non-alcoholic fatty liver disease play a significant role in the development and progression of cardiovascular diseases, accelerating their occurrence, aggravating their course and outcomes. The occurrence and maintenance of a chronic staged course (from fatty hepatosis and non-alcoholic steatohepatitis to progressive liver fibrosis) of the disease is associated with quantitative and qualitative changes in the composition of the intestinal microflora. At the same time, outpatients may consider themselves healthy, which makes it difficult to implement a comprehensive treatment program. The peculiarities of the combination of clinical, laboratory and microbiological characteristics of patients with hepatic steatosis require detailed study for the earliest identification of therapeutic targets, diagnostic and prognostic tools and their effective correction. Purpose of the study: to determine the clinical, laboratory and microbiological characteristics of patients with non-alcoholic fatty liver disease. Material and methods: clinical, laboratory and microbiological data of outpatients were collected, anthropometric indicators were calculated. Statistical analysis: Microsoft Excel 2010 and StatTech v.3.1.8 (Russia) with assessment for normality of distribution and chi-square test. Differences were assessed by nonparametric analysis at a significance level of p&lt;0.05. Results. Patients were assigned to the observation group if they had NAFLD or to the comparison group in it absence. Many patients in the observation group were found to have metabolic syndrome and/or abdominal obesity, accompanied by asthenic syndrome, functional disorders of the biliary tract, and disorders of lipid and carbohydrate metabolism. In the luminal microflora of the intestines of patients in the observation group, the presence of representatives of Pseudomonas spp. was significantly more often detected. Correction of microbiological disorders by adding dietary fiber to the diet provided clinical improvement. Conclusion. In addition to clinical and laboratory data, microbiological characteristics of patients can be used for the earliest diagnosis and effective correction of disorders that occur during the development of NAFLD.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>неалкогольная жировая болезнь печени (НАЖБП)</kwd><kwd>жировой гепатоз</kwd><kwd>амбулаторная помощь</kwd></kwd-group><kwd-group xml:lang="en"><kwd>nonalcoholic fatty liver disease (NAFLD)</kwd><kwd>fatty hepatosis</kwd><kwd>outpatient care</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Brea A., Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk.Int. J. Cardiol. 2013, 167(4): 1109-17. doi: 10.1016/j.ijcard.2012.09.085.</mixed-citation><mixed-citation xml:lang="en">Brea A., Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk.Int. J. Cardiol. 2013, 167(4): 1109-17. doi: 10.1016/j.ijcard.2012.09.085.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Boytsov S. A., Pogosova G. V., Bubnova M. G. et al. Cardiovascular prophylaxis 2017.Russian national guidelines.Russian Journal of Cardiology. 2018;23(6):7-122. (In Russ.) doi: 10.15829/1560-4071-2018-6-7-122.@@ Бойцов С. А., Погосова Г. В., Бубнова М. Г. и др. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;(23):7-122. doi: 10.15829/1560-4071-2018-6-7-122.</mixed-citation><mixed-citation xml:lang="en">Boytsov S. A., Pogosova G. V., Bubnova M. G. et al. Cardiovascular prophylaxis 2017.Russian national guidelines.Russian Journal of Cardiology. 2018;23(6):7-122. (In Russ.) doi: 10.15829/1560-4071-2018-6-7-122.@@ Бойцов С. А., Погосова Г. В., Бубнова М. Г. и др. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;(23):7-122. doi: 10.15829/1560-4071-2018-6-7-122.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Oganov R. G., Maslennikova G. Ya. Individual prevention of cardiovascular diseases. The position of European cardiological societies. Cardiovascular therapy and prevention. 2017;16(1):4-7. (In Russ.) doi: 10.15829/1728-8800-2017-1-4-7.@@ Оганов Р. Г., Масленникова Г. Я. Индивидуальная профилактика сердечно-сосудистых заболеваний. Позиция европейских кардиологических обществ. Кардиоваскулярная терапия и профилактика. 2017;(16):4-7. doi: 10.15829/1728-8800-2017-1-4-7.</mixed-citation><mixed-citation xml:lang="en">Oganov R. G., Maslennikova G. Ya. Individual prevention of cardiovascular diseases. The position of European cardiological societies. Cardiovascular therapy and prevention. 2017;16(1):4-7. (In Russ.) doi: 10.15829/1728-8800-2017-1-4-7.@@ Оганов Р. Г., Масленникова Г. Я. Индивидуальная профилактика сердечно-сосудистых заболеваний. Позиция европейских кардиологических обществ. Кардиоваскулярная терапия и профилактика. 2017;(16):4-7. doi: 10.15829/1728-8800-2017-1-4-7.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Nicoletti A., Ponziani F. R., Biolato M. et al.Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. World J Gastroenterol. 2019;25(33):4814-34. doi: 10.3748/wjg.v25.i33.4814.</mixed-citation><mixed-citation xml:lang="en">Nicoletti A., Ponziani F. R., Biolato M. et al.Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. World J Gastroenterol. 2019;25(33):4814-34. doi: 10.3748/wjg.v25.i33.4814.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ivashkin V. T., Drapkina O. M., Shulpekova Yu. O. Diagnosis and treatment of non-alcoholic fatty liver disease (Methodological recommendations). Moscow: Publishing House «M-Vesti» LLC, 2009. 20 p. (In Russ.)@@ Ивашкин В. Т., Драпкина О. М., Шульпекова Ю. О. Диагностика и лечение неалкогольной жировой болезни печени (Методические рекомендации). М.: ООО «Издательский дом «М-Вести», 2009. 20 с.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V. T., Drapkina O. M., Shulpekova Yu. O. Diagnosis and treatment of non-alcoholic fatty liver disease (Methodological recommendations). Moscow: Publishing House «M-Vesti» LLC, 2009. 20 p. (In Russ.)@@ Ивашкин В. Т., Драпкина О. М., Шульпекова Ю. О. Диагностика и лечение неалкогольной жировой болезни печени (Методические рекомендации). М.: ООО «Издательский дом «М-Вести», 2009. 20 с.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Drapkina O. M., Gatsolaeva D. S., Ivashkin V. T. Nonalcoholic fatty liver disease as a component of metabolic syndrome.Russian Medical News. 2010, 2: 72-8. (In Russ.)@@ Драпкина О. М., Гацолаева Д. С., Ивашкин В. Т. Неалкогольная жировая болезнь печени как компонент метаболического синдрома. Российские медицинские вести. 2010, 2: 72-8.</mixed-citation><mixed-citation xml:lang="en">Drapkina O. M., Gatsolaeva D. S., Ivashkin V. T. Nonalcoholic fatty liver disease as a component of metabolic syndrome.Russian Medical News. 2010, 2: 72-8. (In Russ.)@@ Драпкина О. М., Гацолаева Д. С., Ивашкин В. Т. Неалкогольная жировая болезнь печени как компонент метаболического синдрома. Российские медицинские вести. 2010, 2: 72-8.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis. 2015, 239: 192-202. doi: 10.1016/j.атеросклероз.2015.01.001.</mixed-citation><mixed-citation xml:lang="en">Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis. 2015, 239: 192-202. doi: 10.1016/j.атеросклероз.2015.01.001.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Sprecher D. L., Pearce G. L. How deadly is the “deadly quartet”? A post-CABG evaluation. J. Am. Coll. Cardiol. 2000 Oct;36(4):1159-65. doi: 10.1016/s0735-1097(00)00867-6.</mixed-citation><mixed-citation xml:lang="en">Sprecher D. L., Pearce G. L. How deadly is the “deadly quartet”? A post-CABG evaluation. J. Am. Coll. Cardiol. 2000 Oct;36(4):1159-65. doi: 10.1016/s0735-1097(00)00867-6.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Isomaa B., Almgren P., Tuomi T. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001 Apr;24(4):683-9. doi: 10.2337/diacare.24.4.683.</mixed-citation><mixed-citation xml:lang="en">Isomaa B., Almgren P., Tuomi T. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001 Apr;24(4):683-9. doi: 10.2337/diacare.24.4.683.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ametov A. S., Belykh A. A. Efficiency of correction of disorders of carbohydrate and lipid metabolism in persons with high risk factors.Russian Medical Journal. 2007, No. 28. pp. 2156-2160. (In Russ.)@@ Аметов А. С., Белых А. А. Эффективность коррекции нарушений углеводного и липидного обмена у лиц с высокими факторами риска. Русский медицинский журнал. 2007. № 28. С. 2156-2160.</mixed-citation><mixed-citation xml:lang="en">Ametov A. S., Belykh A. A. Efficiency of correction of disorders of carbohydrate and lipid metabolism in persons with high risk factors.Russian Medical Journal. 2007, No. 28. pp. 2156-2160. (In Russ.)@@ Аметов А. С., Белых А. А. Эффективность коррекции нарушений углеводного и липидного обмена у лиц с высокими факторами риска. Русский медицинский журнал. 2007. № 28. С. 2156-2160.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Recommendations for the management of patients with metabolic syndrome. Clinical recommendations. Ministry of Health of the Russian Federation. 2013. 42 p. (In Russ.) Available at: http://medpoiskpro.ru/terapiya/klinicheskie-rekomendatsii-pokardiologii-2013. Accessed: 30 march 2023. @@ Рекомендации по ведению больных c метаболическим синдромом. Клинические рекомендации. Министерство здравоохранения РФ. 2013. 42 с. URL: http://medpoiskpro.ru/terapiya/klinicheskie-rekomendatsii-pokardiologii-2013.</mixed-citation><mixed-citation xml:lang="en">Recommendations for the management of patients with metabolic syndrome. Clinical recommendations. Ministry of Health of the Russian Federation. 2013. 42 p. (In Russ.) Available at: http://medpoiskpro.ru/terapiya/klinicheskie-rekomendatsii-pokardiologii-2013. Accessed: 30 march 2023. @@ Рекомендации по ведению больных c метаболическим синдромом. Клинические рекомендации. Министерство здравоохранения РФ. 2013. 42 с. URL: http://medpoiskpro.ru/terapiya/klinicheskie-rekomendatsii-pokardiologii-2013.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Machado M., Marques-Vidal P., Cortez-Pinto H. Hepatic histology in obesepatients undergoing bariatric surgery. J. Hepatol. 2016, 45(4):600-6. doi: 10.1016/j.jhep.2006.06.013.</mixed-citation><mixed-citation xml:lang="en">Machado M., Marques-Vidal P., Cortez-Pinto H. Hepatic histology in obesepatients undergoing bariatric surgery. J. Hepatol. 2016, 45(4):600-6. doi: 10.1016/j.jhep.2006.06.013.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Gaggini M., Morelli M., Buzzigoli E., DeFronzo R. A., Bugianesi E., Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013, 5(5): 1544-60. doi: 10.3390/nu5051544.</mixed-citation><mixed-citation xml:lang="en">Gaggini M., Morelli M., Buzzigoli E., DeFronzo R. A., Bugianesi E., Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013, 5(5): 1544-60. doi: 10.3390/nu5051544.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Chang E., Park C. Y., Park S. W. Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J. Diabetes Investig. 2013, 4(6): 517-24. doi: 10.1111/jdi.12107.</mixed-citation><mixed-citation xml:lang="en">Chang E., Park C. Y., Park S. W. Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J. Diabetes Investig. 2013, 4(6): 517-24. doi: 10.1111/jdi.12107.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Williamson R. M., Price J. F., Glancy S., Perry E., Nee L. D., Hayes P. C. et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes Study. Diabetes Care. 2011; 34(5): 1139-44. doi: 10.2337/dc10-2229.</mixed-citation><mixed-citation xml:lang="en">Williamson R. M., Price J. F., Glancy S., Perry E., Nee L. D., Hayes P. C. et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes Study. Diabetes Care. 2011; 34(5): 1139-44. doi: 10.2337/dc10-2229.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Trukhan D. I., Filimonov S. N. Clinic, diagnosis and treatment of major endocrine and hematological diseases. Novokuznetsk: OOO “Polygraphist”, 2015. 119 p. (In Russ.)@@ Трухан Д. И., Филимонов С. Н. Клиника, диагностика и лечение основных эндокринных и гематологических заболеваний. Новокузнецк: ООО «Полиграфист», 2015. 119 с.</mixed-citation><mixed-citation xml:lang="en">Trukhan D. I., Filimonov S. N. Clinic, diagnosis and treatment of major endocrine and hematological diseases. Novokuznetsk: OOO “Polygraphist”, 2015. 119 p. (In Russ.)@@ Трухан Д. И., Филимонов С. Н. Клиника, диагностика и лечение основных эндокринных и гематологических заболеваний. Новокузнецк: ООО «Полиграфист», 2015. 119 с.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Trukhan D. I. Nonalcoholic fatty liver disease associated with obesity: the possibilities of essential phospholipids. Medical advice. Gastroenterology. 2016, 4: 116-122. (In Russ.) doi: 10.21518/2079-701X-2016-9-64-69.@@ Трухан Д. И. Неалкогольная жировая болезнь печени, ассоциированная с ожирением: возможности эссенциальных фосфолипидов. Медицинский совет. Гастроэнтерология. 2016, 4: 116-122. doi: 10.21518/2079-701X-2016-9-64-69.</mixed-citation><mixed-citation xml:lang="en">Trukhan D. I. Nonalcoholic fatty liver disease associated with obesity: the possibilities of essential phospholipids. Medical advice. Gastroenterology. 2016, 4: 116-122. (In Russ.) doi: 10.21518/2079-701X-2016-9-64-69.@@ Трухан Д. И. Неалкогольная жировая болезнь печени, ассоциированная с ожирением: возможности эссенциальных фосфолипидов. Медицинский совет. Гастроэнтерология. 2016, 4: 116-122. doi: 10.21518/2079-701X-2016-9-64-69.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ulluwishewa D., Anderson R., McNabb W. Regulashion of tight junction permeability by intestinal bacteria and Dietary components. J Nutr. 2011; 141(5):769-76. doi: 10.3945/jn.110.135657.</mixed-citation><mixed-citation xml:lang="en">Ulluwishewa D., Anderson R., McNabb W. Regulashion of tight junction permeability by intestinal bacteria and Dietary components. J Nutr. 2011; 141(5):769-76. doi: 10.3945/jn.110.135657.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Zou Y., Lin X., Xue W. et al. Characterization and description of Faecalibacterium butyricigenerans sp. nov. and F. longum sp. nov., isolated from human faeces. Sci Rep. 2021;11:11340. doi: 10.1038/s41598-021-90786-3.</mixed-citation><mixed-citation xml:lang="en">Zou Y., Lin X., Xue W. et al. Characterization and description of Faecalibacterium butyricigenerans sp. nov. and F. longum sp. nov., isolated from human faeces. Sci Rep. 2021;11:11340. doi: 10.1038/s41598-021-90786-3.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Buffie C. G., Bucci V., Stein R. R. et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517(7533):205-8. doi: 10.1038/ nature13828.</mixed-citation><mixed-citation xml:lang="en">Buffie C. G., Bucci V., Stein R. R. et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517(7533):205-8. doi: 10.1038/ nature13828.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Assimakopoulos S. F., Triantos C., Maroulis I., Gogos C. The Role of the Gut Barrier Function in Health and Disease. Gastroenterology Res. 2018;11(4):261-3. doi: 10.14740/gr1053w.</mixed-citation><mixed-citation xml:lang="en">Assimakopoulos S. F., Triantos C., Maroulis I., Gogos C. The Role of the Gut Barrier Function in Health and Disease. Gastroenterology Res. 2018;11(4):261-3. doi: 10.14740/gr1053w.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Alvarez J. et al. Gut microbes and health. Gastroenterol Hepatol. 2021; 44(7):519-535. doi: 10.1016/j.gastre.2021.01.002.</mixed-citation><mixed-citation xml:lang="en">Alvarez J. et al. Gut microbes and health. Gastroenterol Hepatol. 2021; 44(7):519-535. doi: 10.1016/j.gastre.2021.01.002.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Bloomgarden Z. T. Symposium: Debating the Metabolic Syndrome. Medscape Conference Coverage, based on selected sessions. American Diabetes Association 66th Scientific Sessions; June 9-13, 2006, Washington, DC.</mixed-citation><mixed-citation xml:lang="en">Bloomgarden Z. T. Symposium: Debating the Metabolic Syndrome. Medscape Conference Coverage, based on selected sessions. American Diabetes Association 66th Scientific Sessions; June 9-13, 2006, Washington, DC.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Shergill R., Syed W., Rizvi S.A, Singh I. Nutritional support in chronic liver disease and cirrhotics. World J Hepatol. 2018 Oct 27;10(10):685-694. doi: 10.4254/ wjh.v10.i1 0.685.</mixed-citation><mixed-citation xml:lang="en">Shergill R., Syed W., Rizvi S.A, Singh I. Nutritional support in chronic liver disease and cirrhotics. World J Hepatol. 2018 Oct 27;10(10):685-694. doi: 10.4254/ wjh.v10.i1 0.685.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver. Electronic address: easloffi ce@easloffi ce.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liv er disease. J Hepatol. 2019 Jan;70(1):172-193. doi: 10.1016/j. jhep.2018.06.024.</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver. Electronic address: easloffi ce@easloffi ce.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liv er disease. J Hepatol. 2019 Jan;70(1):172-193. doi: 10.1016/j. jhep.2018.06.024.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Henkel A. S., Buchman A. L. Nutritional su pport in patients with chronic liver disease. Nat Clin Pract Gastroenterol Hepatol. 2006 Apr;3(4):202-9. doi: 10.1038/ncpgasthep0443.</mixed-citation><mixed-citation xml:lang="en">Henkel A. S., Buchman A. L. Nutritional su pport in patients with chronic liver disease. Nat Clin Pract Gastroenterol Hepatol. 2006 Apr;3(4):202-9. doi: 10.1038/ncpgasthep0443.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Angulo P. Non-alcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231. doi: 10.1056/NEJMra011775 2.</mixed-citation><mixed-citation xml:lang="en">Angulo P. Non-alcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231. doi: 10.1056/NEJMra011775 2.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Chen P., Torralba M., Tan J. et al. Supplementation of saturated l ong-chain fatty acids maintains intestinal eubiosis and reduces ethanol- induced liver injury in mice. Gastroenterology. 2015 Jan;148(1):203-214.e16. doi: 10.1053/j.gastro.2014.09.014.</mixed-citation><mixed-citation xml:lang="en">Chen P., Torralba M., Tan J. et al. Supplementation of saturated l ong-chain fatty acids maintains intestinal eubiosis and reduces ethanol- induced liver injury in mice. Gastroenterology. 2015 Jan;148(1):203-214.e16. doi: 10.1053/j.gastro.2014.09.014.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Pace A., de Weerth A., Berna M. et al. Pancreas and liver injury are associated in individuals with incr eased alcohol consumption. Clin. Gastroenterol. Clin Gastroenterol Hepatol. 2009 Nov;7(11):1241-6. doi: 10.1016/j.cgh.2009.06.010.</mixed-citation><mixed-citation xml:lang="en">Pace A., de Weerth A., Berna M. et al. Pancreas and liver injury are associated in individuals with incr eased alcohol consumption. Clin. Gastroenterol. Clin Gastroenterol Hepatol. 2009 Nov;7(11):1241-6. doi: 10.1016/j.cgh.2009.06.010.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
